



PRESS RELEASE



October 8, 2019

ArchiMed, European private equity healthcare specialist, announces successful acquisition of OSG by its portfolio company Micromed.

ArchiMed Portfolio Company Micromed secures third strategic acquisition

ArchiMed portfolio company Micromed announces its third strategic acquisition in the neurodiagnostic market.

In a move to strengthen its position as a leader in the field of neurophysiology, European based medical device manufacturer, Micromed, has recently acquired Belgium-based EEG and PSG software company OSG BVBA (OSG).

OSG is strongly positioned in sleep neuromonitoring and clinical neurophysiology with advanced capabilities in Artificial Intelligence (AI) as it relates to sleep scoring and data interpretation.

Sleep neuromonitoring enables early diagnostics of sleep-related neurological conditions, which is a growing concern due to the penetration of Non-Communicable-Diseases, such as obesity or cardiac conditions, among developed countries populations.

One immediate benefit of the acquisition: Micromed will gain direct access to the Benelux market, thanks to OSG's strong position in the area with 230 clients and 50% market penetration in the Netherlands. Micromed will also integrate OSG into its global sales network, offering OSG products in most of Micromed's 78 markets, including the group's key markets of Germany and the United States.

The acquisition also reinforces Micromed's development resources, adding expertise in software development and Artificial Intelligence. The synergies created by combining the companies' product development and R&D teams will enable Micromed to shorten its time to market and more rapidly adapt a broadened and integrated product range to changing market demand.

Micromed has doubled in size within three years through organic growth and acquisitions. The company has also dramatically increased its exposure in the United States and Germany, which now account for more than 50% of sales.

*

**

About ArchiMed - www.archimed-group.eu. ArchiMed is an independent investment firm specialized in the Healthcare industries. It is a strategic and financial partner to European and North American companies operating in the Biopharma, Medtech, Diagnostics, Life Sciences, Healthcare IT, Consumer Health, Public Safety and Care Services sectors.

ArchiMed's international team combines investment, medical, technological and operational experience. It works alongside management teams to accelerate their business growth, through internationalization, product and service range expansion as well as capacity extension, both organically and through acquisitions. Over the last 20 years, ArchiMed's leadership team directly managed and invested in over 40 small, medium and large-size healthcare companies throughout the world, with a combined value above five billion euros.

ArchiMed's investment capacity currently exceeds one billion euros and is potentially twice this amount when including its strategic investment partners.

About Micromed - Founded in 1982, Micromed is a medical device company delivering solutions in Neurophysiology worldwide. Partnering with hospitals, sleep labs and research centers on a global scale, Micromed manufactures and markets high quality, cost effective and clinically relevant neurodiagnostic hardware and software to neurologists, clinicians and researchers for use on adult and pediatric patients. The Micromed product portfolio ranges from Routine, Ambulatory and Video EEG to ECoG, SEEG, PSG, EP, EMG and ICU monitoring solutions for clinical and research applications.

Press Contacts ArchiMed:

France: Stéphanie du Ché, stephanie.duche@archimed-group.eu +33 (0)6 16 36 11 08

International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76